Minerva Surgical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022 at 05:14 pm EST
Share
Minerva Surgical, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was USD 12.59 million compared to USD 12.51 million a year ago. Net loss was USD 11.33 million compared to USD 3.23 million a year ago. Basic loss per share from continuing operations was USD 8 compared to USD 23 a year ago.
For the nine months, sales was USD 36.49 million compared to USD 38.46 million a year ago. Net loss was USD 27.87 million compared to USD 32.27 million a year ago. Basic loss per share from continuing operations was USD 19.6 compared to USD 300.8 a year ago.
Minerva Surgical, Inc. is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. It has established a product line of commercially available, minimally invasive alternatives to hysterectomy, which are designed to address the most common causes of Abnormal Uterine Bleeding (AUB) in most uterine anatomies. Its Minerva Surgical solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the uterus by avoiding unnecessary hysterectomies. It offers a range of solutions, such as the Minerva ES Endometrial Ablation System (Minerva ES), Genesys HTA Endometrial Ablation System (Genesys HTA), Symphion Tissue Removal System (Symphion), and Resectr Tissue Resection Device (Resectr). Minerva ES is an endometrial ablation device that utilizes its PlasmaSense technology.
MINERVA SURGICAL, INC. 